This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a multi-centre randomised trial that was conducted in 17 centres. A randomisation with stratification of the centre and diagnosis was performed. The duration of follow-up was 2 years after transplantation for the effectiveness analysis and data were collected every 30 days. The duration of follow-up was 6 months for the cost analysis.
Analysis of effectiveness
The analysis of the clinical study was conducted on the basis of treatment completers only. The primary health outcome used in the analysis was the time to reach unsupported platelet counts of greater than 25 x10^9 platelets/L. The secondary health outcomes were the time to reach 50 x10^9 platelets/L and the time to become independent from platelet transfusions, neutrophil recovery and the occurrence of acute and chronic graft-versus-host disease (GVHD). Intention to treat analysis was used for survival, relapse and measures of leukaemia-free survival. Patients in the BCT and BMT groups were shown to be comparable at baseline in terms of their age (mean: 37.3 versus 36.5 years), gender (56% versus 52% male) and prognosis factors for GVHD.
Effectiveness results
Blood cell collection led to a higher number of CD34+ and CD3+ cells being collected than did bone marrow collection, (p<10^-6).
The platelet counts of patients in the BCT group reached 25 x10^9 platelets/L 8 days earlier than did those in the BMT group, (p<10^-4). This difference increased to 11 days for the end point of 50 x10^9 platelets/L, (p<10^-5). This, in turn, led to a shorter time period (12 versus 18 days) to reach platelet transfusion independence, (p<10^-4). It also to fewer platelet transfusions (3 versus 6) during the first 180 days after transplantation, (p=0.002).
The median time to reach a neutrophil count of 0.5 x10^9/L was 6 days shorter in the BCT group, (p<0.00001). The median time to reach a count of 1 x10^9 neutrophils/L was also shorter (by 7 days) in the BCT group, (p<0.00001).
The patients in the BCT group were discharged sooner than those in the BMT group, (p<0.03), and were not rehospitalised more often, (p<0.05).
Forty-three patients developed grade 2 or higher acute GVHD. There was no difference between the two groups, 44% for versus 42% for BMT). GVHD occurred more often in the BCT group (50%) than in the BCT group (28%), (p<0.03), and was more severe, (p<0.03).
With a median follow-up of 20 months (range: 6 -35), nine patients (9%) relapsed at a median of 7 months (range: 2 -17) after transplantation. There was no difference between the two groups.
Overall, 31 patients died at a median of 5 months (range: 0.5 -19). There was no difference between the two groups. Two-year overall survival and leukaemia free-survival probabilities reached 66% (range: 56 -75) and 67% (range: 56 -76), respectively. There was no statistical difference between the two groups.
Clinical conclusions
BCT led to a quicker neutrophil and platelet recovery than did BMT.
Measure of benefits used in the economic analysis
The authors did not develop a summary benefit measure. A cost-consequences analysis was therefore performed.
Direct costs
The direct medical costs for 98 patients were estimated for the first 180 days after transplantation. These considered the costs of hospitalisation and visits to the outpatient clinic, transfusions, drugs, conditioning regimen, laboratory tests, and additional tests related to infectious events and parenteral nutrition. The costs of hospitalisation and outpatient visits included the hotel, personnel and the depreciation of equipment. The costs of clinical units were derived from a detailed observation of all consumed resources in physical quantities. The unit costs were estimated using average 1998 French prices. The step-down method was used to calculate the overheads of the unit costs of hospitalisation and outpatient visits. The drug costs were the average purchasing prices in the French Regional Center for Cancer Research and Treatment. The transfusion costs referred to the direct government regulation. The laboratory tests were evaluated using the prices of medical technical acts, established at the national level. The costs and the quantities were not reported separately. Discounting was unnecessary.
Statistical analysis of costs
A statistical analysis of the costs was carried out, but the methods used were not reported.
Indirect Costs
No indirect costs were included in the analysis.
Currency
Euros (Euro).
Sensitivity analysis
No sensitivity analysis was conducted.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
Patients treated with BCT presented a 6% decrease in the total mean cost of the first 180 days, Euro37,410 versus Euro44,531, (p=0.004). However, the graft collection costs were significantly higher, Euro2,740 versus Euro2,449, (p<0.001).
The overall difference was mainly a result of the lower room cost in the BCT group (Euro17,408) than in the BMT group (Euro21,759), (p=0.01).
The difference in the total mean cost between the two groups was emphasised by substantial decreases in the costs of platelet transfusion (Euro934 versus Euro1,887), (p=0.004), laboratory tests (Euro5,220 versus Euro5,832), (p=0.04), and drugs (Euro6,450 versus Euro7,403), (p=0.022).
